 |
Washington Report
Califf Sidesteps Drug Pricing Complaints from Senate
The Senate hearing to weigh the appointment of Robert Califf to be the next commissioner of FDA was a fairly friendly event, with members of the Senate Health, Education, Labor and Pensions (HELP) Committee tossing out mostly softball questions about a range of policies and programs. Jill Wechsler reports
...Read more |
 |
Compliance
Pressure Mounts for Greater Clinical Trial Data Transparency
A report from the Bioethics International finds that for a group of new drugs approved by FDA in 2012, large pharma companies fell “below legal and ethical standards” for making public information from the relevant clinical trials. Jill Wechsler reports
...Read more |
 |
Special Feature
Pharm Exec's Pipeline Report 2016
Will a drug pipeline harvest full of treatments founded on strong science, supportive regulation, and unmet medical need offer solace to shareholders and the promise of a reputational rebound? Will presidential politics add to the pressures on drug pricing, with a sour coda to the old refrain, “in the US, the market decides?” Casey McDonald reports
...Read more |
 |
Regulatory
Hard Times in Washington for Generics
A new report from the Generic Pharmaceutical Association (GPhA) calculates that generic drugs saved $254 billion in 2014, and some $1.68 trillion over the past 10 years. Generics account for 88% of prescriptions, according to analysis by the IMS Institute for Healthcare Informatics, but only 28% of drug spending. Policy makers thus should take steps to promote the development of competitive generic therapies and of biosimilars, says GPhA
...Read more |
Field medical staffing is changing and ratios of field medical to sales force vary by disease area.
 Read the article to learn the benchmarks. |
R&D
Advances in Clinical Outcome Assessments
Joseph Cappelleri and DIA’s Editor in Chief Stephen Spielberg at the importance of clinical outcome assessments (COAs) to the increased emphasis on patient-centered research
...Read more |
In this paper, IMS Health describes the next generation of sales, marketing and technology - Orchestrated Customer Engagement (OCE). OCE seamlessly marshals the sequence, context, and purpose of messages to multiple influencing stakeholders.
Read more |
 |
 //Three months after leaving his role as Vice President of Research and Development Biogen, Doug Williams has been named CEO of startup Codiak BioSciences (Cambridge, MA).//MELA Sciences (Horsham, PA) reported that Christina L. Allgeier has been promoted to the post of Chief Financial Officer.//Paragon Bioservices (Baltimore, MD) announced today the appointment of Robert Roche to the company's Board of Directors.// |
|
|
